Targeting the sting1 gene by crispr activation
AssigneeAarhus Universitet
InventorsStine Høvring GODSK, Kristine Raaby GAMMELGAARD, Martin Roelsgaard JAKOBSEN, Rasmus Otkjær BAK, Anders ETZERODT
Life of this patent
Estimating the term…
Abstract
The present invention relates to CRISPRa constructs targeting STING for use in cancer treatment. In particular, the present invention relates to CRISPRa constructs targeting STING for use in treatment of cancers having no or low STING expression.
Claims26
A CRISPR activation (CRISPRa) composition or a CRISPRa combination comprising
- a)
- an RNA molecule encoding a deactivated RNA-guided endonuclease, such as dCas, preferably dCas9;
- or
- a deactivated RNA-guided endonuclease, such as dCas, preferably dCas9;
- and
- b) a guide RNA complementary to a part of STING DNA;
- and
- c) a transcriptional activator
- encoded by the RNA molecule encoding the deactivated RNA-guided endonuclease;
- or
- fused to the deactivated RNA-guided endonuclease;
- wherein the guide RNA binds to STING DNA within SEQ ID NO:
- 28 or the complementary sequence of SEQ ID NO:
- 28.
A method of preventing, treating and/or ameliorating a cancer in a subject in need thereof, said method comprising administering a CRISPRa composition or CRISPRa combination subject in need thereof;
- said CRISPRa composition or CRISPRa combination comprising
- a)
- an RNA molecule encoding a deactivated RNA-guided endonuclease;
- or
- a deactivated RNA-guided endonuclease;
- and
- b) a guide RNA complementary to a part of STING DNA;
- and
- c) a transcriptional activator
- encoded by the RNA molecule encoding the deactivated RNA-guided endonuclease;
- or
- fused to the deactivated RNA-guided endonuclease;
- wherein the guide RNA binds to STING DNA within SEQ ID NO:
- 28 or the complementary sequence of SEQ ID NO:
- 28.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.